Becton, Dickinson and Company (BDX)

Market Cap	41.17B -29.9%
Revenue (ttm)	22.23B +6.5%
Net Income	1.14B -24.0%
EPS	3.99 -22.8%
Shares Out	275.54M
PE Ratio	25.94
Forward PE	11.29
Dividend	$4.20 (2.81%)
Ex-Dividend Date	Jun 9, 2026

Volume	4,481,662
Open	153.87
Previous Close	153.26
Day's Range	146.49 - 155.28
52-Week Range	143.00 - 213.08
Beta	0.29
Analysts	Buy
Price Target	184.54 (+23.5%)
Earnings Date	May 7, 2026

About BDX

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, va...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Apr 23, 1962
• Employees: 72,000
• Stock Exchange: NYSE
• Ticker Symbol: BDX
• Website: https://www.bd.com

Financial Performance

In fiscal year 2025, BDX's revenue was $21.84 billion, an increase of 8.24% compared to the previous year's $20.18 billion. Earnings were $1.68 billion, a decrease of -1.58%.

Analyst Summary

According to 13 analysts, the average rating for BDX stock is "Buy." The 12-month stock price target is $184.54, which is an increase of 23.50% from the latest price.

Price Target

$184.54

(23.50% upside)

Analyst Consensus: Buy